Aim We investigated whether steroid therapy for Crohn's disease (CD) 
Introduction

Loss of bone mineral density (BMD) has been reported as a common complication of inflammatory bowel disease (IBD) in Western countries, and patients with Crohn's disease (CD) have an especially high risk of developing osteoporosis (1). In Japan, there have been several studies on the complications induced by steroid therapy in ulcerative colitis (UC)
. Patients with UC who received more than 10,000 mg of steroids are recommended to undergo a total colectomy before any osteoporotic manifestations develop. However, there are few reports on the relationship between the loss of BMD (5) and the effects of steroid therapy in Japanese patients with CD. Since the treatment for CD in Japan has shifted from nutritional therapy to drug therapy, including steroids, there is an increasing focus on the bone complications from steroids. Although the general guidelines for steroid-induced osteoporosis have been published (6) , the prevention and optimal treatment for bone disease in patients with CD still needs to be established. As a secondgeneration bisphosphonate drug, alendronate is a potent and selective inhibitor of osteoclasts (7) . It has been reported that alendronate therapy significantly increases the BMD in CD patients in Europe and the USA (8, 9) , but there have been no reports in Japan. Therefore, we investigated whether steroid therapy for Japanese CD patients influences the BMD, and whether alendronate is effective in improving this loss of BMD. 
F i g u r e 1 . Re l a t i o n s h i p b e t we e n t h e t o t a l s t e r o i d d o s e a n d d i s e a s e d u r a t i o n i n o u t p a t i e n t s wi t h Cr o h n ' s d i s e a s e ( n = 1 6 ) .
T a b l e 1 . Co mp a r i s o n o f P a t i e n t s wi t h L o w a n d
Biochemical markers of bone metabolism
In five out of the 6 steroid user-patients undergoing alendronate treatment, serum and urine samples were obtained for the measurement of biochemical markers of bone turnover. Serum bone-specific alkaline phosphatase (BAP) as a marker of bone formation was measured by an enzyme immunoassay. The urinary excretion of cross-liked Ntelopeptides from type X collagen (NTx) corrected for the creatinine concentration was used as a maker of bone resorption, and was measured by an enzyme-linked immunosorbent assay.
Statistical analysis
The results are expressed as means ± SD. Comparisons between group means were performed using student's unpaired t-test or a chi-squared test, as appropriate, and the slopes were evaluated using regression methods. A p value < 0.05 was taken to be statistically significant.
Results
The amount of total steroids (as prednisolone) and the duration of disease among the patients with CD is shown in Fig. 1 . There are two main groups of patients receiving steroids treatment. One is the steroid-never user (4 patients) , and the other is the steroid-dependent user (12 patients There are no statistically differences between vitamin K2 and alendronate groups F i g u r e 3 . P e r c e n t a g e c h a n g e i n t h e T s c o r e f r o m b a s e l i n e o v e r 1 y r f o r t h e wh o l e b o d y , l u mb a r s p i n e L 2 -L 4 , a n d l e f t f e mo r a l n e c k i n p a t i e n t s t a k i n g v i t a mi n K2 ( wh i t e b a r , n = 9 ) o r a l e n d r o n a t e ( b l a c k b a r , n = 6 ) . T h e v a l u e s r e p r e s e n t me a n s ± S D. * * p < 0 . 0 1 b e t we e n b a s e l i n e a n d a f t e r o n e y e a r . Ch a n g e s i n t h e s e r u m B AP ( a ) a n d NT x ( b ) l e v e l s d u r i n g a l e n d r o n a t e t r e a t me n t . T h e  d a t a v a l u e s a r e e x p r e s s e d a s me a n s ± S D . n = 5 . * p < 0 . 0 5 b e t we e n p r e -t r e a t me n t a n d 6 mo n t h s o f t r e a t me n t . (Fig. 4) .
Discussion
The present study showed for the first time that steroid therapy decreased the BMD in a dose-dependent manner in Japanese CD patients. The number of patients in this study was only 16 (11) (12) (13) (14) (15) (16) (17) . In this study, most patients had been on nutritional therapy, which means that most patients were supported by a balanced caloric diet, and nutritional deficiencies would be unlikely to occur. Recently, an analysis from the TREAT study in the USA showed that steroid therapy for CD patients exerts a harmful effect on the prognosis, including being prone to infection (18) . Therefore (24) . Recent reports have demonstrated that maintenance infliximab treatment is associated with an improved BMD in CD patients (25) . Therefore, replacing steroid-dependent therapy to infliximab therapy with steroid termination is strongly desirable from the viewpoint of preventing BMD loss.
In conclusion, the BMD of Japanese CD and UC patients decreased depending on the total amount of steroids administered, and the oral administration of steroid and alendronate improved this loss of BMD induced by the steroids.
